Revogene C. difficile | Meridian Bioscience

Improves satisfaction among patients and physicians by providing rapid, accurate, actionable results for the detection of Clostridium difficile infection (CDI)

Catalog Number: 410300

Support & Documents

Why Revogene C. difficile?

Revogene provides healthcare systems an opportunity to minimize the overall burden of C. difficile through improved care and efficiency by helping to reduce the risk of missing a true positive with the accuracy of molecular. Fast, actionable results enable physicians to make informed decisions about patient management and treatment resulting in reduced healthcare costs associated with isolation and antibiotics. Revogene is a flexible, reliable molecular platform that allows health systems to provide testing closer to the patient and advance the quality of care through simplified sample processing and efficient workflow.

Efficient workflow - Sample to result in 3 easy steps
Flexible platform - Run multiple assays with different sample types on a single run
Platform for growth - Single analyte and multiplex testing capability
Total solution - Can be paired with Meridian immunoassays for a scalable testing solution

"The system is very easy to work with, I was able to start and run an experiment after only 5 minutes of training!"

Ingrid Op den Buijs

Senior technician molecular diagnostics
PAMM Laboratories
Veldhoven, Netherlands

Definitive answers, confidence in results

Contact Sales

Definitive answers, confidence in results

Contact Sales

Support & Documents

Downloadable PDFs

Revogene C. difficile Brochure

Procedure Card
Revogene C. difficile

Package Insert
Revogene C. difficile

Safety Data Sheet
Revogene C. difficile Kit

CLSI
Revogene C. difficile

SDS
Revogene C. difficile

Package Insert
Revogene Mock Pie

Safety Data Sheet
Revogene Sample Buffer

Safety Data Sheet
Sample Buffer (OSHA)

FAQs

Colonization is more common than C. diff infection. The patient exhibits NO clinical symptoms (asymptomatic) but may test positive for the C.diff organism or its toxin gene. With infection, the patient exhibits clinical symptoms and tests positive for the C.diff organism and/or its toxin.

Use a stool toxin test as part of a multi-step algorithm (ie, glutamate dehydrogenase [GDH] plus toxin; GDH plus toxin, arbitrated by nucleic acid amplification test [NAAT]; or NAAT plus toxin) rather than a NAAT alone for all specimens received in the clinical laboratory when there are no pre-agreed institutional criteria for patient stool submission.

Use a NAAT alone or a multi-step algorithm for testing (ie, GDH plus toxin; GDH plus toxin, arbitrated by NAAT; or NAAT plus toxin) rather than a toxin test alone when there are pre-agreed institutional criteria for patient stool submission.

There is insufficient data to recommend the use of biologic markers as an adjunct to diagnosis.

Revogene C. difficile – 87493

Why Revogene C. difficile?

Definitive answers, confidence in results

Definitive answers, confidence in results

Support & Documents

Downloadable PDFs

FAQs

What are the differences between colonization and infection?

What is the best-performing method (ie, in use positive and negative predictive value) for detecting patients at increased risk for clinically significant C. difficile infection in commonly submitted stool specimens?

What is the most sensitive method of diagnosis of CDI in stool specimens from patients likely to have CDI based on clinical symptoms?

Does detection of fecal lactoferrin or another biologic marker improve the diagnosis of CDI over and above the detection of toxigenic C. difficile? Can such a subset predict a more ill cohort?

What is the suggested CPT Code?

Get in Touch With US